CD155 expression and its clinical significance in non‑small cell lung cancer

Oyama,Rintaro; Kanayama,Masatoshi; Mori,Masataka; Matsumiya,Hiroki; Taira,Akihiro; Shinohara,Shinji; Takenaka,Masaru; Yoneda,Kazue; Kuroda,Koji; Tanaka,Fumihiro

doi:10.3892/ol.2022.13286

CD155 expression and its clinical significance in non‑small cell lung cancer

Authors:
- Rintaro Oyama
- Masatoshi Kanayama
- Masataka Mori
- Hiroki Matsumiya
- Akihiro Taira
- Shinji Shinohara
- Masaru Takenaka
- Kazue Yoneda
- Koji Kuroda
- Fumihiro Tanaka
View Affiliations

Affiliations: Second Department of Surgery (Chest Surgery), University of Occupational and Environmental Health, Kitakyushu, Fukuoka 807‑8555, Japan
Published online on: March 29, 2022 https://doi.org/10.3892/ol.2022.13286
Article Number: 166
Copyright: © Oyama et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

CD155 serves an important role in tumor progression by promoting cell proliferation and migration. CD155 is also involved in the immune evasion of tumor cells, which may cause the development and progression of tumors. Accordingly, CD155 has emerged as a novel target in cancer immunotherapy; however, its expression in lung cancer remains unclear. To assess CD155 expression and its prognostic significance, 96 patients with completely resected pathologic stage I adenocarcinoma of the lung were retrospectively reviewed. Immunohistochemical staining was performed to evaluate CD155 expression on tumor cells. Expression levels of programmed death‑ligand 1 (PD‑L1), another molecule participating in immune evasion, were also evaluated immunohistochemically. CD155 expression was positive in 37 patients (38.5%). CD155‑positivity was associated with aggressive tumor behavior, such as pleural invasion and vascular invasion. In addition, CD155‑positivity was a significant factor to predict a poor prognosis (5‑year overall survival (OS) rate, 63.3% for CD155‑positive patients vs. 93.1% for CD155‑negative patients; P<0.001). Patients harboring tumors with positive CD155 and PD‑L1 expression showed the poorest prognosis (5‑year OS rate, 44.4% for both‑positive patients vs. 85.4% for the other patients; P<0.001). The positive expression status of both CD155 and PD‑L1 was a significant and independent unfavorable prognostic factor (hazard ratio, 3.86; 95% confidence interval, 1.51‑9.89; P=0.004; in a multivariate analysis). In conclusion, CD155‑positivity was associated with aggressive tumor behavior, and was a factor to predict a poor prognosis. Its prognostic impact was enhanced when combined with PD‑L1 expression status. These results should be validated in a large‑scale study.

View Figures

View References

1	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI
2	Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, et al: Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 29 (Suppl 4):iv192–iv237. 2018. View Article : Google Scholar
3	Beatty GL and Gladney WL: Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 21:687–692. 2015. View Article : Google Scholar : PubMed/NCBI
4	Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. 2012. View Article : Google Scholar : PubMed/NCBI
5	Sharma P, Hu-Lieskovan S, Wargo JA and Ribas A: Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 168:707–723. 2017. View Article : Google Scholar : PubMed/NCBI
6	Andrews LP, Yano H and Vignali DAA: Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: Breakthroughs or backups. Nat Immunol. 20:1425–1434. 2019. View Article : Google Scholar : PubMed/NCBI
7	Yeo J, Ko M, Lee DH, Park Y and Jin HS: TIGIT/CD226 axis regulates anti-tumor immunity. Pharmaceuticals (Basel). 14:2002021. View Article : Google Scholar : PubMed/NCBI
8	Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, Park S, Javinal V, Chiu H, Irving B, et al: The immunoreceptor TIGIT regulates antitumor and antiviral CD8⁺ T cell effector function. Cancer Cell. 26:923–937. 2014. View Article : Google Scholar : PubMed/NCBI
9	Attili I, Tarantino P, Passaro A, Stati V, Curigliano G and de Marinis F: Strategies to overcome resistance to immune checkpoint blockade in lung cancer. Lung Cancer. 154:151–160. 2021. View Article : Google Scholar : PubMed/NCBI
10	Hirai A, Yoneda K, Shimajiri S, Kuroda K, Hanagiri T, Fujino Y and Tanaka F: Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung. J Thorac Cardiovasc Surg. 155:382–392.e1. 2018. View Article : Google Scholar : PubMed/NCBI
11	Sugaya M, Uramoto H, Uchiyama A, Nagashima A, Nakanishi R, Sakata H, Nakanishi K, Hanagiri T and Yasumoto K: Phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel in patients with completely resected non-small cell lung cancer. Anticancer Res. 30:3039–3044. 2010.PubMed/NCBI
12	Uramoto H, Nakanishi R, Nagashima A, Uchiyama A, Inoue M, Osaki T, Yoshimatsu T, Sakata H, Nakanishi K and Yasumoto K: A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer. Anticancer Res. 30:4695–4699. 2010.PubMed/NCBI
13	Talbot D and Massamba VK: A descriptive review of variable selection methods in four epidemiologic journals: There is still room for improvement. Eur J Epidemiol. 34:725–730. 2019. View Article : Google Scholar : PubMed/NCBI
14	Nakai R, Maniwa Y, Tanaka Y, Nishio W, Yoshimura M, Okita Y, Ohbayashi C, Satoh N, Ogita H, Takai Y and Hayashi Y: Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma. Cancer Sci. 101:1326–1330. 2010. View Article : Google Scholar : PubMed/NCBI
15	Sun Y, Luo J, Chen Y, Cui J, Lei Y, Cui Y, Jiang N, Jiang W, Chen L, Chen Y, et al: Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma). Int Immunopharmacol. 80:1061982020. View Article : Google Scholar : PubMed/NCBI
16	Lee BR, Chae S, Moon J, Kim MJ, Lee H, Ko HW, Cho BC, Shim HS, Hwang D, Kim HR and Ha SJ: Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade. JCI Insight. 5:e128632020. View Article : Google Scholar
17	Huang WC, Kuo KT, Wang CH, Yeh CT and Wang Y: Cisplatin resistant lung cancer cells promoted M2 polarization of tumor-associated macrophages via the Src/CD155/MIF functional pathway. J Exp Clin Cancer Res. 38:1802019. View Article : Google Scholar : PubMed/NCBI
18	You H, Zhang YZ, Lai HL, Li D, Liu YQ, Li RZ, Khan I, Hsiao WW, Duan FG, Fan XX, et al: Prognostic significance of tumor poliovirus receptor and CTLA4 expression in patients with surgically resected non-small-cell lung cancer. J Cancer Res Clin Oncol. 146:1441–1450. 2020. View Article : Google Scholar : PubMed/NCBI
19	Lee JB, Hong MH, Park SY, Chae S, Hwang D, Ha SJ, Shim HS and Kim HR: Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma. Sci Rep. 11:85512021. View Article : Google Scholar : PubMed/NCBI
20	Zhang H, Yang Z, Du G, Cao L and Tan B: CD155-prognostic and immunotherapeutic implications based on multiple analyses of databases across 33 human cancers. Technol Cancer Res Treat. 20:15330338209800882021.PubMed/NCBI
21	Müller S, Mayer S, Möller P, Barth TFE and Marienfeld R: Spatial distribution of immune checkpoint proteins in histological subtypes of lung adenocarcinoma. Neoplasia. 23:584–593. 2021. View Article : Google Scholar : PubMed/NCBI
22	Gao J, Zheng Q, Xin N, Wang W and Zhao C: CD155, an onco-immunologic molecule in human tumors. Cancer Sci. 108:1934–1938. 2017. View Article : Google Scholar : PubMed/NCBI